PriceTargets.com logo

Phathom Pharmaceuticals - PHAT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 208.72%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.45 As of 12/20/2024 06:31 PM ET
▼ -0.37 (-4.73%)

This chart shows the closing price for PHAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phathom Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHAT

Analyst Price Target is $23.00
▲ +208.72% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Phathom Pharmaceuticals in the last 3 months. The average price target is $23.00, with a high forecast of $28.00 and a low forecast of $12.00. The average price target represents a 208.72% upside from the last price of $7.45.

This chart shows the closing price for PHAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Phathom Pharmaceuticals. This rating has held steady since October 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
12/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
9/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
9/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
8/9/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$10.00 ➝ $12.00
7/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
7/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
7/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
7/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
5/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
5/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
5/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
5/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
5/3/2024Stifel NicolausInitiated CoverageBuy$24.00
4/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
4/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
4/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
3/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
3/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
2/23/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
2/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
2/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
1/5/2024Needham & Company LLCBoost TargetBuy ➝ Buy$23.00 ➝ $26.00
11/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
11/3/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$9.00 ➝ $10.00
9/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
8/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
8/9/2023HC WainwrightInitiated CoverageBuy ➝ Buy$28.00
5/11/2023Evercore ISIUpgradeIn-Line ➝ Outperform
4/19/2023Needham & Company LLCReiterated RatingBuy$23.00
4/5/2023Needham & Company LLCReiterated RatingBuy$23.00
3/13/2023Craig HallumInitiated CoverageBuy$21.00
3/1/2023BMO Capital MarketsLower TargetOutperform$35.00 ➝ $30.00
2/10/2023BMO Capital MarketsInitiated CoverageBuy$35.00
2/10/2023Needham & Company LLCLower TargetBuy$25.00 ➝ $23.00
1/10/2023GuggenheimLower Target$30.00 ➝ $22.00
1/4/2023Needham & Company LLCLower TargetBuy$38.00 ➝ $25.00
1/4/2023BMO Capital MarketsLower TargetOutperform$38.00 ➝ $35.00
11/14/2022BMO Capital MarketsLower TargetOutperform$45.00 ➝ $38.00
11/11/2022GuggenheimLower TargetBuy$42.00 ➝ $30.00
10/20/2022Jefferies Financial GroupInitiated CoverageBuy$16.00
8/3/2022BMO Capital MarketsLower Target$54.00 ➝ $45.00
8/3/2022The Goldman Sachs GroupLower TargetNeutral$15.00 ➝ $9.00
8/3/2022Needham & Company LLCLower TargetBuy$44.00 ➝ $38.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$32.00 ➝ $15.00
10/18/2021GuggenheimBoost TargetBuy$66.00 ➝ $75.00
9/30/2021Needham & Company LLCInitiated CoverageBuy$55.00
5/12/2021The Goldman Sachs GroupUpgradeSell ➝ Neutral$40.00 ➝ $48.00
2/17/2021BMO Capital MarketsInitiated CoverageOutperform$63.00
2/2/2021GuggenheimInitiated CoverageBuy$60.00
1/28/2021JonestradingInitiated CoverageBuy
12/15/2020Needham & Company LLCBoost TargetBuy$45.00 ➝ $55.00
8/7/2020Needham & Company LLCReiterated RatingBuy$45.00
6/26/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$34.00
5/12/2020Needham & Company LLCInitiated CoverageBuy$45.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 12 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 12 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Phathom Pharmaceuticals logo
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Read More

Today's Range

Now: $7.45
Low: $7.39
High: $7.83

50 Day Range

MA: $12.11
Low: $7.45
High: $18.94

52 Week Range

Now: $7.45
Low: $6.07
High: $19.71

Volume

2,475,979 shs

Average Volume

922,597 shs

Market Capitalization

$509.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Phathom Pharmaceuticals?

The following equities research analysts have issued reports on Phathom Pharmaceuticals in the last twelve months: HC Wainwright, Needham & Company LLC, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for PHAT.

What is the current price target for Phathom Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Phathom Pharmaceuticals in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 208.7%. Needham & Company LLC has the highest price target set, predicting PHAT will reach $28.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $12.00 for Phathom Pharmaceuticals in the next year.
View the latest price targets for PHAT.

What is the current consensus analyst rating for Phathom Pharmaceuticals?

Phathom Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PHAT.

What other companies compete with Phathom Pharmaceuticals?

Other companies that are similar to Phathom Pharmaceuticals include NewAmsterdam Pharma, IDEAYA Biosciences, Centessa Pharmaceuticals, Recursion Pharmaceuticals and ImmunityBio. Learn More about companies similar to Phathom Pharmaceuticals.

How do I contact Phathom Pharmaceuticals' investor relations team?

Phathom Pharmaceuticals' physical mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The company's listed phone number is 877-742-8466 and its investor relations email address is [email protected]. The official website for Phathom Pharmaceuticals is www.phathompharma.com. Learn More about contacing Phathom Pharmaceuticals investor relations.